Description
Indications
Rabeprazole Gastro-resistant pills are used to treat the following conditions: Active duodenal ulcers
A gastric ulcer that is active and benign
Gastroesophageal reflux disease (GERD) is symptomatic, erosive, or ulcerative (GERD).
Gastro-esophageal Reflux Disease (GERD) is a disease that affects the esophagus and Long-term planning (GERD Maintenance)
Symptomatic treatment for gastroesophageal reflux disease (GERD) ranging from mild to severe (symptomatic GERD)
Syndrome of Zollinger-Ellison
Helicobacter pylori eradication in patients with peptic ulcer disease in combination with appropriate antimicrobial treatment regimens.
Pharmacology
Rabeprazole inhibits the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell, which decreases gastric acid secretion. Rabeprazole has been classified as a gastric proton pump inhibitor since this enzyme is thought to be the acid (proton) pump within the parietal cell.
Dosage & Administration
Active Duodenal Ulcer and Active Benign Gastric Ulcer: The recommended oral dose for both bioactive duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning. Most patients with active duodenal ulcers heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcers heal within six weeks. However, again a few patients may require an additional six weeks of therapy to achieve healing.
Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.
Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.
Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen of taking 10 mg once daily when needed.
Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses of up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.
Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.
Interaction
Gastric acid secretion is profoundly and long-lastingly inhibited by respite. It’s possible that you’ll come into contact with a substance whose absorption is pH-dependent. When rabeprazole sodium is used with ketoconazole or itraconazole, antifungal plasma levels may be significantly reduced. When ketoconazole or itraconazole are used together with Respite, individual patients may need to be watched to see if a dosage adjustment is necessary. There was no interaction with liquid antacids. Atazanavir’s absorption is pH-dependent. As a result, PPIs, such as rabeprazole, should not be taken with atazanavir.
Contraindications
Hypersensitivity to the active ingredient or any excipient. Rabeprazole is not recommended during pregnancy or nursing.
Side Effects
Rabeprazole is generally well tolerated in both short and long-term studies. Headache, diarrhea, abdominal discomfort, vomiting, constipation, dry mouth, increased or decreased hunger, muscle soreness, sleepiness, and dizziness are all possible side effects of rabeprazole.
Pregnancy & Lactation
Pregnancy category ‘C’ according to the US Food and Drug Administration. Rabeprazole has been studied in animals, and there has been no evidence of reduced fertility or injury to the fetus as a result of its use. However, no suitable and well-controlled studies in pregnant women have been conducted. Because rabeprazole is likely to be excreted in human milk, a choice should be taken on whether to stop breastfeeding or stop taking the medication, taking into account the drug’s importance to the mother.
Precautions & Warnings
Because a symptomatic response to Rabeprazole therapy does not rule out the presence of stomach or esophageal cancer, the potential of cancer should be ruled out before starting treatment with Rabeprazole 20 mg Gastro-resistant Tablets.
Patients on long-term treatment (especially those who have been on it for more than a year) should be monitored on a frequent basis.
Proton pump inhibitors, especially when used in high dosages and for long periods of time (>1 year), can raise the risk of hip, wrist, and spine fractures, especially in the elderly or in the presence of other known risk factors. Proton pump inhibitors may raise the total risk of fracture by 10–40%, according to observational studies. Other risk factors may have contributed to some of the increase. Patients at risk of osteoporosis should be monitored and supplemented with vitamin D and calcium as needed.
It’s impossible to rule out the possibility of cross-hypersensitivity interactions with other proton pump inhibitors or substituted benzimidazoles.
Rabeprazole gastro-resistant pills should not be chewed or mashed, but rather eaten whole.
Post-marketing reports of blood dyscrasias have been reported (thrombocytopenia and neutropenia). When an alternate etiology could not be found, the occurrences were usually straightforward and resolved after the rabeprazole was stopped.
Hepatic enzyme abnormalities have been observed in clinical trials and published since the drug’s approval. When an alternate etiology could not be found, the occurrences were usually straightforward and resolved after the rabeprazole was stopped.
Generic
Rabeprazole Sodium
Therapeutic Class
Inhibitor of the proton pump.
Storage Conditions
Keep the temperature below 30°C and away from light and moisture. Keep out of children’s reach.
Pharmaceutical Name
Popular Pharmaceuticals Ltd.